ESPR

$2.55-0.05 (-1.92%)

Market ClosedAs of Mar 20, 8:00 PM UTC

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPROTranscriptsPROStatementsPRO

Historical Price

Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.55
Potential Upside
5%
Whystock Fair Value$2.68
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryDrug Manufacturers-Specialty & Generic

Esperion Therapeutics, Inc., a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C) in the United States. The company's marketed products include NEXLETO...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$654.87M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
1.11
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
23.45%
Quick Ratio
Tight liquidity. Monitor cash flow carefully against debt.
0.70

Recent News

Insider Monkey
Mar 20, 2026

Esperion (ESPR) Highlights Inclusion of Bempedoic Acid in 2026 ACC/AHA Dyslipidemia Guidelines

Esperion Therapeutics, Inc. (NASDAQ:ESPR) is one of the 11 Best High Volume Penny Stocks to Buy Now. On March 16, 2026, Esperion highlighted the inclusion of bempedoic acid in the 2026 American College of Cardiology/American Heart Association Multisociety Guideline on the Management of Dyslipidemia. The guidelines support the use of bempedoic acid across multiple patient […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 16, 2026

Esperion Therapeutics Touts 38% Revenue Growth, Corstasis Deal and 2026 Cash-Gen Path at Conference

Executives from Esperion Therapeutics (NASDAQ:ESPR) highlighted accelerating revenue growth, plans to expand its commercial footprint, and details of a pending acquisition during remarks at the Citizens Life Sciences Conference in Miami, coming a day after the company reported earnings. 2025 result

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
GuruFocus.com
Mar 10, 2026

Esperion Therapeutics Inc (ESPR) Q4 2025 Earnings Call Highlights: Record Revenue Growth and ...

Esperion Therapeutics Inc (ESPR) reports a 144% revenue surge in Q4 2025, driven by strategic partnerships and successful commercial execution.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Mar 10, 2026

Esperion Therapeutics Q4 Earnings Call Highlights

Esperion Therapeutics (NASDAQ:ESPR) executives told investors the company delivered its “strongest performance to date” in 2025 and is entering 2026 with what management described as strong commercial momentum, an improving balance sheet, and an agreement to acquire Corstasis Therapeutics and its ne

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Zacks
Mar 10, 2026

Esperion Therapeutics (ESPR) Misses Q4 Earnings Estimates

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of -5.38% and +4.90%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

BEARISH
Negative press. News cycle fixated on risk factors or misses.